MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
devdiscourse17h
Personalized therapy for anxiety: The promise of AI-driven healthcare
AI-driven tools harness ML algorithms to provide insights into anxiety disorders. Supervised ML models, such as logistic ...
Always Anxious? Creativity’s The Cure, According To Book ‘Beyond Anxiety’
Calming exercises can help tame anxiety, but a creative life is a cure-all according to author Martha Beck: “Anxiety can’t ...
News Medical on MSN1d
Antidepressants reduce anxiety, but long-term impact remains unclear
A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.
New Atlas10h
Students punished at school struggle more with anxiety and depression
A study out of the University of Minnesota has revealed that kids who face various forms of exclusionary discipline (ED) at school were at greater risk of developing anxiety and depression. The ...
This condition shares a lot of its symptoms with anxiety — but it’s much more serious
“Hyperthyroidism is often linked to Graves’ disease, another autoimmune condition that overstimulates the thyroid. Thyroid nodules, which are abnormal lumps in the thyroid, and excessive iodine can ...
Optimistic Buy Rating for Mind Medicine’s MM120 Amid Promising Phase 3 Progress and Strong Phase 2b Results
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Mind Medicine (MNMD – Research Report). The associated price ...
Review confirms that antidepressants reduce anxiety, but long-term impact remains unclear
A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under ...
Mind Medicine doses first patient in Panorama study
Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, ...
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
Hosted on MSN6d
What’s the Best Way to Deal with Anxiety?
Are you worried, restless, or having trouble concentrating most of the time? It could be anxiety. This common mental health ...